|
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Clinical research trials and Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH). Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) clinical trial. Human subjects often get the best healthcare possible for their Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)  Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)
For Condition: Cardiovascular Diseases,Heart Diseases,Heart Failure,Heart Failure, Congestive
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To conduct a randomized, unblinded clinical trial comparing the left ventricular assist device (LVAD) with maximum medical management in patients with end-stage heart failure who were not candidates for heart transplantation.
Details: BACKGROUND: Mortality rates for heart failure are high, with five year survival rates approximating 30 to 40 percent in patients with mild to moderate symptoms and 0 to 20 percent survival in patients with severe symptoms. The patient with class IV heart failure has a one year survival rate of only 40 to 50 percent. This is despite advances in medical therapy and the availability of ACE inhibitors. While cardiac transplantation is the most viable form of treatment for these patients, it is limited by complications of chronic immunosuppression, the development of graft coronary artery disease and the serious shortage of donor organs. As many as 16,500 patients per year may be suitable candidates for heart transplantation. The actual number of donor hearts procured over the past few years, however, has remained relatively constant at 2,000. Thus, there is a strong rationale for the therapeutic application of left ventricular assist devices (LVADs) as an alternative to cardiac transplantation. With respect to LVAD efficacy, patients have been supported for periods as long as 344 days on the pneumatic system and 503 days with the electromechanical device. Experience with the TCI pneumatic system in 75 LVAD patients show improved one year survival after transplantation in the LVAD patients as opposed to patients who did not receive the LVAD despite the same selection criteria. Experience with the vented electric LVADs in bridge patients show a transplant and survival rate that is similar to the pneumatic device. LVADs have also been shown to have a favorable effect on circulatory hemodynamics and exercise capacity. Among 53 patients who survived the TCI LVAD procedure, 90 percent improved to New York Heart Association (NYHA) functional class I and 10 percent to functional class II. With respect to safety, the principal adverse effects associated with the LVADs include bleeding, hemolysis, and organ dysfunction, thromboembolism, infection, right heart failure, and mechanical failure. Thromboembolic complications are low in the TCI device despite the lack of systemic anticoagulation. The overall mechanical failure rate is small, less than 1 percent in 26 patient years of use. The vented electric and pneumatic device experience to date indicates that the devices are similar with respect to adverse event rates. Thus, in 1997 there was a strong rationale for a randomized controlled trial that compared the benefits and cost of vented electric LVADs to medical treatment. The need to perform a randomized controlled study was further emphasized by the lack of rigorous data on survival, quality of life, and cost effectiveness comparing LVAD support with medical therapy. DESIGN NARRATIVE: Unblinded, randomized, multicenter. Patients were randomized to either the Thermo Cardiosystems, Inc. (TCI) vented electric (VE) LVAD or optimal medical therapy (OMM) and followed for at least two years. If randomized to LVAD therapy, patients received a LVAD implantation within 12 hours of randomization. If randomized to medical therapy, patients received optimal medical management including the use of digoxin, diuretics, and ACE inhibitors in maximally tolerated doses. The primary endpoint was all-cause mortality. Secondary endpoints included cardiovascular mortality, exercise capacity (six-minute walk test) and health-related quality of life, adverse effects, and the relative cost-effectiveness of LVADs versus medical management. Recruitment ended in June, 2001.
Eligibility:
Study Type: Interventional, Treatment, Randomized
Minimum Age/Maximum Age: 18 Years/72 Years
Genders: Both
Protocol Entry Criteria: Men and women with Class III and Class IV congestive heart failure patients between the ages of 18 and 72 who were not candidates for heart transplantation.
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 110;
Study Start Date: October 1997
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000607
Other Heart Diseases Studies:
1. Congestive Heart Failure Trends in the Elderly 1970-94
2. DECIPHER STICH - Ancillary to STICH
3. Honolulu Heart Program
4. Prevalence of Asymptomatic Ventricular Dysfunction
5. Heart Failure Adherence and Retention Trial (HART)
Related Studies:
Other Heart Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)
|
|
|
|
|
|
|
|
